Wednesday, April 15, 2026 MAC28 (NRG BR007) intergroup trial will be closed to accrual after reaching the accrual goal of 1670 patients. A memo has been posted to the MAC28 trial page.CCTG MAC28 (NRG BR007) is A Phase III Clinical Trial Evaluating De-Escalation ofBreast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score ≤ 18 Breast Cancer (DEBRA)The purpose of this study is to compare the usual treatment of breast radiation and hormonal drugs after lumpectomy to using hormonal drugs alone for 50 to 70 year old people with low risk breast cancer. The removal of breast radiation from the usual treatment may reduce side effects. Researchers want to find out if this approach is better or worse than the usual approach for low-risk breast cancer.
